Long-term Leqembi Treatment Shows Growing Benefits for Alzheimer's Patients Over Five Years
New Five-Year Study on Leqembi Treatment
BioArctic AB's partner, Eisai, has recently unveiled significant findings from the Clarity AD study at the 19th Clinical Trials on Alzheimer's Disease conference held in Boston. These results stem from a comprehensive five-year analysis on the continuous treatment with Leqembi (lecanemab), revealing growing clinical advantages over time for early Alzheimer's disease patients.
Significant Clinical Outcomes
The research demonstrated that 62% of patients treated with Leqembi at an early stage of Alzheimer's, characterized by low tau protein levels in their brains, saw noteworthy improvements in cognitive functions and daily activity capabilities, as assessed by the Clinical Dementia Rating-Sum of Boxes (CDR-SB). This finding strongly suggests the critical impact of early intervention in managing this debilitating disease.
The Clarity AD study involved a rigorous placebo-controlled Phase 3 methodology with nearly 1,800 participants. Out of this pool, 898 received the infusion of Leqembi bi-weekly while the remaining 897 were administered a placebo. Impressive engagement was shown, with a vast majority (95%) opting to continue into the long-term extension phase of the study, with 351 patients completing five years of continuous Leqembi treatment.
As the treatment duration extended, the divergence in rates of cognitive and functional decline between patients receiving Leqembi and historical Alzheimer's disease data became increasingly pronounced. Analyses indicated 1.00 point less decline in CDR-SB scores after three years, escalating to 2.05 points after five years of treatment.
Early Treatment Yields Greater Benefits
The study also incorporated a tau PET substudy, facilitating the identification of patients at earlier stages of Alzheimer's. After five years, an impressive 66% of participants exhibiting low tau levels experienced no cognitive or functional decline. Furthermore, 62% showed marked improvement when compared to their baseline assessments. This reinforces the notion that initiating treatment early is essential in harnessing the maximum therapeutic benefits of Leqembi.
Longitudinal assessments across various scales, including ADAS-Cog14 and ADCS MCI-ADL, corroborated these findings. Patients treated with Leqembi faced a 36% relative risk reduction in advancing to more severe stages of Alzheimer's compared to data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). After five years, 61.9% of the Leqembi group progressed to the next stage versus 77.5% from the ADNI group.
Additionally, the risk of transitioning from early Alzheimer's to moderate or severe dementia was diminished by 49%, where only 31% of Leqembi-treated patients progressed, compared to 48.7% in the ADNI cohort.
Safety Profile Consistency
Eisai reported that the safety profile of Leqembi remained stable over the five-year trajectory. Notably, side effects like ARIA-E were most prevalent within the initial six months and then gradually subsided in subsequent years. Analyzing incidences across twelve-month intervals revealed a decline in ARIA-E occurrences, with only 0.6% reported in the final period compared to 1.7% in the placebo group.
Alzheimer's disease is characterized by a persistent degenerative process marked by amyloid-beta and tau proteins. Leqembi aims to offset this through dual mechanisms—actively targeting both protofibrils and established amyloid plaque, addressing the core pathology of the disease.
Eisai recognizes the urgency of early treatment as a strategy to mitigate the progression of Alzheimer's disease effectively. Their continued research endeavors signify a commitment to developing life-altering therapies for those battling this complex illness.
As of now, Leqembi is approved in 53 nations, with further evaluations underway in multiple regions. Its potential to significantly alter the trajectory of Alzheimer's makes Leqembi a beacon of hope for patients and caregivers alike.
Conclusion
The findings regarding Leqembi underscore the importance of early and sustained treatment in Alzheimer's disease management. By continuing to study its long-term impacts, researchers hope to unveil even more insights that can help combat this relentless disease.
This study presents a crucial advancement in Alzheimer's treatment and serves as a compelling reason for the medical community to prioritize early intervention strategies.